Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside other therapeutics and with various complex co-morbidities.
With the growth of…
Continue Reading
For patients managing chronic conditions, medication adherence plays a crucial role in successful treatment. However, adherence rates are alarmingly low, with only about 50% of patients consistently following prescribed regimens. This lack of adherence…
Continue Reading
Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients.
Compounded GLP-1s are custom-made by compounding pharmacies and include the same…
Continue Reading
Obstructive sleep apnea (OSA) is a serious, chronic sleep-related breathing disease that impacts an estimated 80 million people in the United States and nearly 1 billion globally. Untreated OSA carries profound health and quality-of-life…
Continue Reading
As we enter another new year, healthcare leaders are closely watching trends that are poised to reshape the industry.
Leaders from Red Cell Partners — a McLean, Virginia-based investment and incubation firm that funds, builds,…
Continue Reading
The Unprecedented Rise in Medicaid’s Diabetes Drug Spending
Introduction to the Crisis
Medicaid faces a staggering projection of $29.9 billion in expenditure for type 2 diabetes and weight loss medications, according to a recent report from…
This month, online healthcare booking platform Zocdoc released an end-of-the-year report detailing various trends in patient behavior. The report — based on data from the millions of visitors Zocdoc sees each month — noted…
Continue Reading
The current healthcare systems in the U.S. often compartmentalize health conditions, treating physical and mental health as distinct entities. This dissociative approach has led to a limited perspective on diabetes treatment focused largely on…
Continue Reading
At a time when self-insured employers are searching for ways to address escalating healthcare costs, the rise of GLP-1 drugs for weight loss poses some interesting questions for employers. Could investment in these pricey…
Continue Reading
